The aim of the EVOLVE study is to observe and assess drug administration activities, time spent on drug administration activities, and patient-reported outcomes (PROs) including quality of life, treatment satisfaction, and patient perception of devices related to use of United Therapeutics Corporation (UTC)-developed next-generation infusion pumps to administer Remodulin in patients with pulmonary arterial hypertension.
The study requires eligible participants to remotely complete assessments and questionnaires (i.e., no office visits required) using a mobile app over a period of 8 weeks. Eligible participants may enroll in this study at any time before and up to 10 days after starting subcutaneous Remodulin therapy using the Remunity pump for Remodulin (treprostinil) injection for pulmonary arterial hypertension (PAH). Participants may have other medical data about them recorded, such as medical history.
Read more about the EVOLVE study at this link on the clinicaltrials.gov website
Discalimer
While every possible effort will be taken to ensure that the Pulmonary Hypertension Knowledge Sharing Platform content is accurate and up-to-date, it may still include opinions of experts that are the best knowledge at the time of publication but may now be outdated, and materials that are otherwise inaccurate or incomplete. We invite visitors to consult with their health care professionals before making any decisions based upon them.